Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.
Novartis drug Scemblix is the first in a new class of drugs known as STAMP inhibitors. European Commission approval of the small molecule provides a new treatment option for chronic myeloid leukemia that is resistant to earlier treatments, as well as those cases in which patients cannot tolerate the other therapies for this blood cancer.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Some patients reach a point where ongoing TKI therapy can cause more harm than good. New data can simplify the decision to discontinue treatment.